vs

Side-by-side financial comparison of DYNEX CAPITAL INC (DX) and TREACE MEDICAL CONCEPTS, INC. (TMCI). Click either name above to swap in a different company.

TREACE MEDICAL CONCEPTS, INC. is the larger business by last-quarter revenue ($62.5M vs $43.5M, roughly 1.4× DYNEX CAPITAL INC). On growth, DYNEX CAPITAL INC posted the faster year-over-year revenue change (531.3% vs -9.0%). Over the past eight quarters, DYNEX CAPITAL INC's revenue compounded faster (75.8% CAGR vs 10.6%).

Dynex Capital Inc. is a publicly traded real estate investment trust headquartered in the United States. It specializes in investing in and managing a diversified portfolio of mortgage-backed securities, residential and commercial mortgage loans, and other mortgage-related assets. It delivers consistent returns to shareholders via regular dividends and long-term capital growth.

Treace Medical Concepts, Inc. is a medical device company, headquartered in Ponte Vedra Beach, Florida, specializing in the design, manufacture, and marketing of foot and ankle surgical devices and biologics. Lapiplasty, Treace’s novel primary surgical product, advanced the treatment of bunions, surgically correcting the metatarsal bone, for the first time, in all three dimensions.

DX vs TMCI — Head-to-Head

Bigger by revenue
TMCI
TMCI
1.4× larger
TMCI
$62.5M
$43.5M
DX
Growing faster (revenue YoY)
DX
DX
+540.3% gap
DX
531.3%
-9.0%
TMCI
Faster 2-yr revenue CAGR
DX
DX
Annualised
DX
75.8%
10.6%
TMCI

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DX
DX
TMCI
TMCI
Revenue
$43.5M
$62.5M
Net Profit
$-9.4M
Gross Margin
80.6%
Operating Margin
-9.5%
Net Margin
-15.0%
Revenue YoY
531.3%
-9.0%
Net Profit YoY
-1775.0%
EPS (diluted)
$1.59
$-0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DX
DX
TMCI
TMCI
Q4 25
$43.5M
$62.5M
Q3 25
$30.6M
$50.2M
Q2 25
$23.1M
$47.4M
Q1 25
$17.1M
$52.6M
Q4 24
$68.7M
Q3 24
$45.1M
Q2 24
$44.5M
Q1 24
$-3.2M
$51.1M
Net Profit
DX
DX
TMCI
TMCI
Q4 25
$-9.4M
Q3 25
$150.4M
$-16.3M
Q2 25
$-13.6M
$-17.4M
Q1 25
$-3.1M
$-15.9M
Q4 24
$-501.0K
Q3 24
$-15.4M
Q2 24
$-21.2M
Q1 24
$40.1M
$-18.7M
Gross Margin
DX
DX
TMCI
TMCI
Q4 25
80.6%
Q3 25
79.1%
Q2 25
79.7%
Q1 25
79.7%
Q4 24
80.7%
Q3 24
80.1%
Q2 24
80.2%
Q1 24
80.2%
Operating Margin
DX
DX
TMCI
TMCI
Q4 25
-9.5%
Q3 25
-31.2%
Q2 25
-35.8%
Q1 25
-29.6%
Q4 24
-0.3%
Q3 24
-33.6%
Q2 24
-48.1%
Q1 24
-37.1%
Net Margin
DX
DX
TMCI
TMCI
Q4 25
-15.0%
Q3 25
491.3%
-32.4%
Q2 25
-58.8%
-36.7%
Q1 25
-18.0%
-30.3%
Q4 24
-0.7%
Q3 24
-34.1%
Q2 24
-47.7%
Q1 24
-1256.8%
-36.5%
EPS (diluted)
DX
DX
TMCI
TMCI
Q4 25
$1.59
$-0.14
Q3 25
$1.08
$-0.26
Q2 25
$-0.14
$-0.28
Q1 25
$-0.06
$-0.25
Q4 24
$-0.01
Q3 24
$-0.25
Q2 24
$-0.34
Q1 24
$0.64
$-0.30

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DX
DX
TMCI
TMCI
Cash + ST InvestmentsLiquidity on hand
$531.0M
$48.4M
Total DebtLower is stronger
$55.6M
Stockholders' EquityBook value
$2.5B
$87.3M
Total Assets
$17.3B
$190.6M
Debt / EquityLower = less leverage
0.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DX
DX
TMCI
TMCI
Q4 25
$531.0M
$48.4M
Q3 25
$491.0M
$57.4M
Q2 25
$387.5M
$69.3M
Q1 25
$327.4M
$76.1M
Q4 24
$75.7M
Q3 24
$82.8M
Q2 24
$95.0M
Q1 24
$295.7M
$110.0M
Total Debt
DX
DX
TMCI
TMCI
Q4 25
$55.6M
Q3 25
$53.5M
Q2 25
$53.5M
Q1 25
$53.4M
Q4 24
$53.3M
Q3 24
$53.2M
Q2 24
$53.2M
Q1 24
$53.1M
Stockholders' Equity
DX
DX
TMCI
TMCI
Q4 25
$2.5B
$87.3M
Q3 25
$2.0B
$89.2M
Q2 25
$1.6B
$97.6M
Q1 25
$1.4B
$105.3M
Q4 24
$112.9M
Q3 24
$104.9M
Q2 24
$112.1M
Q1 24
$958.5M
$126.4M
Total Assets
DX
DX
TMCI
TMCI
Q4 25
$17.3B
$190.6M
Q3 25
$14.2B
$196.6M
Q2 25
$11.3B
$206.4M
Q1 25
$9.0B
$205.8M
Q4 24
$217.1M
Q3 24
$212.9M
Q2 24
$226.1M
Q1 24
$6.3B
$242.7M
Debt / Equity
DX
DX
TMCI
TMCI
Q4 25
0.64×
Q3 25
0.60×
Q2 25
0.55×
Q1 25
0.51×
Q4 24
0.47×
Q3 24
0.51×
Q2 24
0.47×
Q1 24
0.42×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DX
DX
TMCI
TMCI
Operating Cash FlowLast quarter
$120.8M
$-8.0M
Free Cash FlowOCF − Capex
$-10.4M
FCF MarginFCF / Revenue
-16.7%
Capex IntensityCapex / Revenue
3.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-29.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DX
DX
TMCI
TMCI
Q4 25
$120.8M
$-8.0M
Q3 25
$68.3M
$-9.1M
Q2 25
$31.9M
$-3.0M
Q1 25
$6.4M
$4.2M
Q4 24
$-4.2M
Q3 24
$-11.8M
Q2 24
$-13.9M
Q1 24
$-17.1M
$-7.2M
Free Cash Flow
DX
DX
TMCI
TMCI
Q4 25
$-10.4M
Q3 25
$-11.9M
Q2 25
$-7.8M
Q1 25
$655.0K
Q4 24
$-7.3M
Q3 24
$-14.7M
Q2 24
$-15.6M
Q1 24
$-11.1M
FCF Margin
DX
DX
TMCI
TMCI
Q4 25
-16.7%
Q3 25
-23.7%
Q2 25
-16.5%
Q1 25
1.2%
Q4 24
-10.6%
Q3 24
-32.6%
Q2 24
-35.2%
Q1 24
-21.8%
Capex Intensity
DX
DX
TMCI
TMCI
Q4 25
3.8%
Q3 25
5.6%
Q2 25
10.1%
Q1 25
6.7%
Q4 24
4.5%
Q3 24
6.4%
Q2 24
3.9%
Q1 24
7.7%
Cash Conversion
DX
DX
TMCI
TMCI
Q4 25
Q3 25
0.45×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-0.43×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons